Aranesp (darbepoetin alfa) — HCPCS J0881 / J0882

J0881 vs J0882 — the indication split CMS HCPCS verified May 2026

Same drug, same vials, same ASP. Different code by indication. Wrong code = denial.

Aranesp (darbepoetin alfa) is unusual: CMS assigned two permanent J-codes for the same product, differentiated only by clinical indication. The split exists because of how Medicare pays for ESRD-related drugs — J0882 is bundled into the ESRD PPS per-treatment composite rate, while J0881 is paid fee-for-service under Part B.

ESA class comparison CMS HCPCS verified May 2026

Aranesp is the longest-acting ESA. Different molecules, different J-codes, different dosing intervals.

Dosing & unit math FDA label (Aranesp PI)

From FDA prescribing information for Aranesp (BLA 103951).

CKD anemia — NDD-CKD (J0881)

• Initiation: 0.45 mcg/kg SC or IV every 4 weeks; or 0.75 mcg/kg every 2 weeks
• Initiate when Hgb <10 g/dL, after iron-replete confirmation (TSAT >20%, ferritin >100 ng/mL)
• Target Hgb 10–11 g/dL (CMS / KDIGO); reduce or hold dose when Hgb >11 g/dL
• Maintenance: titrate q2–4 weeks based on Hgb response
• Bill J0881 with units = actual mcg administered

CKD anemia — ESRD on dialysis (J0882)

• Initiation: 0.45 mcg/kg IV (preferred for HD) or SC every week; conversion from epoetin alfa per FDA conversion table
• Same target Hgb 10–11 g/dL
• Bill J0882 on ESRD facility claim (UB-04, TOB 072x); bundled into PPS

Chemotherapy-induced anemia — CIA (J0881)

• 2.25 mcg/kg SC weekly — titrate to 4.5 mcg/kg if Hgb increase <1 g/dL after 6 weeks
• OR fixed-dose 500 mcg SC every 3 weeks (more common in clinical practice)
• Initiate only when minimum 2 additional months of chemo are planned and Hgb <10 g/dL
• Discontinue if no response after 8 weeks (Hgb increase <1 g/dL)
• Discontinue when chemo course ends (per Boxed Warning)
• REMS: ESA APPRISE Oncology Program enrollment required

Worked example — NDD-CKD induction, 80 kg patient

Worked example — CIA fixed dose, 70 kg patient

Iron sufficiency required before ESA

Per FDA label, KDIGO, and most payer LCDs: confirm iron-replete status (TSAT >20%, ferritin >100 ng/mL for NDD-CKD; TSAT >30%, ferritin >500 ng/mL for HD) before initiating Aranesp. Iron deficiency is a top cause of ESA non-response and a frequent payer denial reason if iron studies are not documented in the chart.

NDC reference FDA NDC Directory verified May 2026

Administration codes CPT verified May 2026

Aranesp is supportive care, NOT a chemotherapy agent. Use therapeutic injection codes.

Modifiers CMS verified May 2026

JZ — required when no waste

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. Aranesp ships in single-dose prefilled syringes with no overfill — if the ordered dose matches a syringe strength exactly (e.g., 60 mcg ordered for a 60 mcg PFS), append JZ to the J0881/J0882 line.

JW — report wasted drug

When a weight-based dose doesn't match an available syringe strength exactly (e.g., 36 mcg ordered, 40 mcg PFS used — 4 mcg discarded), bill the administered units on the JZ-style line and the wasted units on a separate line with JW. The wasted drug is reimbursable but must be explicitly reported. One of JZ or JW must be on every J0881 / J0882 claim.

AY — ESRD beneficiary, non-ESRD condition

Append AY when an ESRD beneficiary on dialysis receives Aranesp for a clearly non-ESRD reason (e.g., chemotherapy-induced anemia during active chemo for solid tumor). AY allows the ESA charge to be paid separately outside the ESRD PPS bundle. Use J0881 (not J0882) with AY in this scenario, on the appropriate Part B claim. Document the non-ESRD condition (e.g., D64.81, cancer C-code, Z51.11) explicitly.

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the injection. Routine pre-injection vitals + Hgb review is bundled.

340B modifiers (JG, TB)

For 340B-acquired Aranesp, follow your MAC's current 340B modifier policy. Most ESRD facilities do not participate in 340B; office-based oncology and nephrology buy-and-bill may use 340B with the appropriate JG or TB modifier per payer instructions.

ICD-10-CM by indication FY2026 verified May 2026

Site of care & place of service Verified May 2026

ESRD PPS bundling — the J0882 reimbursement reality CMS ESRD PPS verified May 2026

Effective January 1, 2011, ESAs are bundled into the ESRD Prospective Payment System per-treatment composite rate.

Before 2011, dialysis centers separately billed ESAs (J0882, J0885, J0886, J0888) as Part B drugs at ASP + 6%. The 2011 ESRD PPS folded ESAs and most ESRD-related drugs and lab tests into a single per-treatment composite payment. The PPS base rate is updated annually; for CY2026 the base rate is approximately $277 per treatment (post-budget-neutrality adjustment), with case-mix and facility-level adjusters applied.

What that means in practice

• J0882 still appears on the ESRD claim (UB-04, TOB 072x) for reporting and audit purposes
• The drug cost is not separately reimbursed beyond the PPS composite rate
• Facilities cannot mark-up J0882 above ASP and pass it through
• The economic incentive is to minimize ESA use while staying within the Hgb 10–11 g/dL window — a key driver of the post-2011 dose reduction trend
• For non-ESRD conditions in an ESRD beneficiary (most commonly CIA during chemo), use J0881 + AY modifier for separate Part B payment

Outliers and exceptions

ESRD beneficiaries who are at home (e.g., self-administering subcutaneous Aranesp via SureClick) under home dialysis arrangements are still subject to PPS bundling. Acute kidney injury (AKI) patients receiving temporary dialysis are NOT under PPS — bill J0881 fee-for-service.

Payer policy snapshot — Hgb targets and PA Reviewed May 2026

All major payers enforce target Hgb 10–11 g/dL and require iron-replete confirmation before initiation.

Step therapy

Some commercial payers (UHC, Cigna) require step therapy through Retacrit (epoetin alfa-epbx biosimilar, Q5105/Q5106) before approving Aranesp for non-cancer indications, on cost grounds. The cancer indication typically does NOT require step therapy due to dosing-frequency advantages of Aranesp. Verify per-payer.

Boxed warning FDA class warning 2007

Class-wide history

The FDA added the boxed warning to the entire ESA class in March 2007 after multiple trials (CHOIR, CREATE, BEST) demonstrated worse outcomes when ESAs were dosed to higher Hgb targets in CKD and cancer populations. The warning was strengthened in 2011 with explicit dosing guidance to use the lowest dose and to maintain Hgb in the 10–11 g/dL range. The cancer-specific REMS (ESA APPRISE) was rolled out in 2010 and remains active.

ESA APPRISE REMS — required for cancer use FDA REMS verified May 2026

The ESA APPRISE Oncology Program (Assisting Providers and Cancer Patients with Risk Information for the Safe Use of ESAs) is a Risk Evaluation and Mitigation Strategy (REMS) jointly held by Amgen (Aranesp) and Janssen (Procrit). Enrollment is required for any provider prescribing Aranesp or Procrit for chemotherapy-induced anemia.

REMS requirements

• Prescriber enrollment — complete training module, certify with the program
• Hospital / institution enrollment — if ESA dispensed in inpatient setting
• Patient counseling — review the ESA APPRISE risks with each cancer patient before each chemo course
• Patient and Healthcare Professional Acknowledgment Form — signed by both, kept in chart, before each chemo course
• NOT required for the CKD anemia indication (NDD-CKD or ESRD)

Contact

• ESA APPRISE Program: 1-866-284-8089
• Web: esa-apprise.com

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter. J0881 ASP is identical to J0882 ASP — same drug.

Coverage

No NCD specific to Aranesp; multiple MAC LCDs cover ESAs in CKD and CIA (e.g., Novitas L34624, NGS L33616, Palmetto L36277). All MACs cover J0881/J0882 for FDA-approved on-label indications with documented Hgb, iron studies, and (for cancer) REMS enrollment. Hgb >11 g/dL within the billing month is a near-universal denial trigger.

Code history

• J0881 — non-ESRD use, permanent code, effective January 1, 2007
• J0882 — ESRD on dialysis, permanent code, effective January 1, 2007
• Pre-2007 darbepoetin alfa was billed under transitional Q-codes
• 2011: J0882 brought into ESRD PPS bundle (1/1/2011)

Patient assistance — Amgen Assist 360 Amgen verified May 2026

• Amgen Assist 360 (FIRST STEP): 1-888-427-7478 (1-888-4ASSIST) / amgenassist360.com — benefits investigation, prior authorization assistance, appeal support, copay help, and PAP referral. Single number for all Amgen products.
• Aranesp Co-pay Card (commercial): first dose as low as $5 for eligible commercially-insured patients; ongoing copay assistance up to annual cap. Excludes Medicare, Medicaid, and federal program patients.
• Amgen Safety Net Foundation: free product for uninsured / underinsured patients meeting income requirements (administered through the independent 501(c)(3) Amgen Safety Net Foundation).
• Foundations (Medicare patients): for CKD anemia, refer to Patient Access Network (PAN) Foundation, HealthWell, NeedyMeds — verify open CKD funds quarterly. For CIA, oncology funds at PAN, CancerCare, and HealthWell.

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Aranesp?

Aranesp (darbepoetin alfa) has two permanent HCPCS codes for the same drug, selected by indication: J0881 "Injection, darbepoetin alfa, 1 mcg (non-ESRD use)" and J0882 "Injection, darbepoetin alfa, 1 mcg (for ESRD on dialysis)." Each microgram equals one billable unit on both codes. J0881 is used for NDD-CKD anemia and chemotherapy-induced anemia; J0882 is used when the patient is on dialysis for ESRD. Same ASP, different code — code selection error is a top denial.

When do I bill J0881 vs J0882 for Aranesp?

J0881 = non-ESRD use: NDD-CKD (CKD stages 3–5 not on dialysis), chemotherapy-induced anemia in non-myeloid malignancies, and any other on-label non-dialysis use. J0882 = ESRD on dialysis (in-center HD or PD). For Medicare in-center hemodialysis patients, J0882 is bundled into the ESRD PPS per-treatment payment and is not separately billable on the Part B claim. ICD-10 ESRD code Z99.2 plus N18.6 should accompany J0882. Wrong code = denial; cannot be re-billed under the alternate code without correction.

How many units do I bill for a 60 mcg Aranesp dose?

60 units. 1 mcg = 1 unit on both J0881 and J0882. A 0.45 mcg/kg dose for an 80 kg NDD-CKD patient is 36 mcg = 36 units. A 2.25 mcg/kg dose for a 70 kg cancer patient is approximately 158 mcg administered (using 150 mcg syringe + waste, or 200 mcg syringe with waste). Always bill the actual mcg administered, not the syringe size.

What administration CPT do I use for Aranesp?

For Aranesp given in office or infusion suite (non-dialysis setting): CPT 96372 "Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular" for SC administration (most common), or 96365 "Therapeutic IV infusion, up to 1 hour" for IV push/infusion. For ESRD patients receiving Aranesp during dialysis under the ESRD PPS, the administration is bundled into the per-treatment payment — do NOT bill admin separately. Aranesp is NOT a chemotherapy drug; do NOT use 96401 or 96413.

Is Aranesp bundled into the ESRD PPS?

Yes. Effective January 1, 2011, ESAs administered to Medicare beneficiaries with ESRD on in-center hemodialysis or home dialysis are bundled into the ESRD Prospective Payment System (PPS) per-treatment composite rate. J0882 still appears on the ESRD claim (Type of Bill 072x) for reporting purposes but is not separately reimbursed beyond the PPS base rate. For NDD-CKD patients (not yet on dialysis), J0881 is separately payable under Part B fee-for-service.

What is the Medicare reimbursement for J0881?

For Q2 2026, the Medicare Part B payment limit for J0881 is approximately $3.072 per mcg (ASP + 6%). A standard NDD-CKD induction dose of 0.45 mcg/kg q4w for an 80 kg patient (36 mcg) reimburses at approximately $110.59 per dose. A chemotherapy-induced anemia dose of 500 mcg q3w reimburses at approximately $1,536.00 per dose. J0882 ASP is identical, but bundled into ESRD PPS for in-center HD beneficiaries. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%.

Does Aranesp have a boxed warning?

Yes. Aranesp carries a class-wide ESA boxed warning for: (1) Increased risk of death, serious cardiovascular events, thromboembolism, and stroke when ESAs are dosed to target Hgb >11 g/dL; (2) In cancer patients, shortened overall survival and/or increased risk of tumor progression or recurrence in some studies. ESAs should be used only when the alternative is transfusion, and discontinued when the chemotherapy course ends. Use the lowest dose to avoid transfusion. The cancer indication requires enrollment in the ESA APPRISE Oncology Program (REMS).

Is REMS required for Aranesp?

Yes — for the cancer indication only. Prescribers and hospitals must enroll in the ESA APPRISE Oncology Program (Assisting Providers and Cancer Patients with Risk Information for the Safe Use of ESAs) to prescribe Aranesp or Procrit/Epogen for chemotherapy-induced anemia. REMS includes prescriber training, patient counseling on risks, and a signed Patient and Healthcare Professional Acknowledgment Form before each chemo course. REMS is not required for the CKD anemia indication.

What target hemoglobin does Medicare expect for Aranesp?

Medicare and most commercial payers enforce the FDA-labeled target Hgb range of 10–11 g/dL for both CKD and chemo-induced anemia indications. Initiate ESA when Hgb <10 g/dL, hold or reduce when Hgb >11 g/dL, and discontinue when Hgb is no longer responsive. UnitedHealthcare and Aetna LCDs/policies will deny J0881/J0882 claims when documented Hgb >11 g/dL within the billing month. Iron-replete confirmation (TSAT >20%, ferritin >100 ng/mL) is also required before initiation.

Source documents

1. DailyMed — ARANESP (darbepoetin alfa) Prescribing Information
   FDA-approved label (BLA 103951); 2007 class boxed warning, 2011 dosing strengthened
2. FDA Aranesp label PDF (current revision)
   Boxed warning + ESA APPRISE REMS
3. Amgen Assist 360 — Aranesp HCP support
   Benefits investigation, PA support, copay programs · 1-888-427-7478
4. ESA APPRISE Oncology Program (REMS)
   Required for cancer indication; jointly held by Amgen + Janssen · 1-866-284-8089
5. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026
6. CMS — ESRD Prospective Payment System
   Bundling rules effective 1/1/2011; CY2026 PPS Final Rule
7. KDIGO Clinical Practice Guideline for Anemia in CKD (2012, updated)
   Target Hgb 10–11 g/dL; iron-replete prerequisites
8. ASCO/ASH Joint Clinical Practice Guideline — ESAs in Cancer (2019 update)
   Use only with concurrent chemo, lowest dose to avoid transfusion
9. UnitedHealthcare — ESA Medical Drug Policy
10. Aetna CPB 0195 — Erythropoiesis-Stimulating Agents
11. SEER CanMED — HCPCS J0881 / J0882 reference
12. FDA National Drug Code Directory

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 2, 2026 — Initial publication. ASP data: Q2 2026. Manufacturer source: Amgen 2025 (Aranesp PI + Amgen Assist 360 HCP page). FDA boxed warning class-wide 2007 (2011 strengthened). ESRD PPS bundling effective 1/1/2011. Both J0881 (non-ESRD) and J0882 (ESRD) covered.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. The J0881 vs J0882 split, ESRD PPS bundling rules, target Hgb 10–11 g/dL, and ESA APPRISE REMS scope are all verified against primary CMS, FDA, and manufacturer sources. We do not paraphrase from billing-software vendor blogs.

See also

• Epogen / Procrit (J0885) — short-acting epoetin alfa
• Retacrit (Q5105 / Q5106) — epoetin alfa-epbx biosimilar
• Reblozyl (J0896) — non-ESA anemia therapy for MDS / beta-thalassemia